Insider Transactions in Q2 2022 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2022
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
16,402
-1.45%
|
$65,608
$4.34 P/Share
|
|
Jun 23
2022
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
19,855
-1.57%
|
$79,420
$4.34 P/Share
|
|
Jun 23
2022
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,635
-1.11%
|
$6,540
$4.34 P/Share
|
|
May 20
2022
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,127
-7.59%
|
$36,381
$3.7 P/Share
|
|
May 20
2022
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
136,421
-10.75%
|
$409,263
$3.7 P/Share
|
|
May 20
2022
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
139,791
-9.95%
|
$419,373
$3.7 P/Share
|
|
Apr 25
2022
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
8,509
-0.6%
|
$25,527
$3.84 P/Share
|
|
Apr 25
2022
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
5,107
-0.4%
|
$15,321
$3.84 P/Share
|
|
Apr 25
2022
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
703
-0.44%
|
$2,109
$3.84 P/Share
|
|
Apr 25
2022
|
Dexcel Pharma Technologies Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,600
+0.01%
|
$25,800
$3.91 P/Share
|
|
Apr 22
2022
|
Dexcel Pharma Technologies Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
31,685
+0.03%
|
$95,055
$3.83 P/Share
|